NEW YORK (GenomeWeb News) – Rosetta Genomics has priced a public offering of 5.5 million shares of common stock at $5 per share, the firm said today.

The microRNA diagnostics developer said it expects gross proceeds from the offering to be around $27.5 million. It expects to close the financing on or around Aug. 8, and it has granted underwriters an option to purchase 825,000 shares to cover over-allotments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.